Virtual screening of bioactive anti-SARS-CoV natural products and identification of 3β,12-diacetoxyabieta-6,8,11,13-tetraene as a potential inhibitor of SARS-CoV-2 virus and its infection related pathways by MD simulation and network pharmacology
Since the first prevalence of COVID-19 in 2019, it still remains the most devastating pandemic throughout the world. The current research aimed to find potential natural products to inhibit the novel coronavirus and associated infection by MD simulation and network pharmacology approach. Molecular d...
Saved in:
Similar Items
-
Concerns regarding SARS-CoV-2 JN.1 mutations should be raised
by: Roney, Miah, et al.
Published: (2024) -
Evolution of SARS-CoV-2 from BA.2.86 to JN.1 variations and detection in Bangladesh
by: Roney, Miah, et al.
Published: (2024) -
The SARS-CoV-2 variants and their impacts
by: Akmal Shukri, Amir Muhaimin, et al.
Published: (2022) -
Pathophysiology, histopathology and therapeutic of SARS-CoV-2
by: Noman, Efaq, et al.
Published: (2020) -
Lateral flow immunoassays for SARS-CoV-2
by: Ang, Geik Yong, et al.
Published: (2022)